Fujian Cosunter Pharmaceutical Co., Ltd. Class A

Fujian Cosunter Pharmaceutical Co., Ltd. Class A

SSZSE:300436
67.59
CNY
-3.21
(-4.53%)
-1.48EPS
14.06BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.59
4.54
2.76
2.21
2.12
2.93
2.96
2.63
2.48
2.42
2.65
2.77
2.61
2.66
Basic EPS, GAAP
0.51
1.5
0.92
0.47
0.24
0.12
0.08
0.11
-0.23
-0.8
-2.19
-0.98
-1.37
-1.3
Free Cash Flow per Basic Share
0.37
1.36
0.71
-0.06
0.26
-1.59
-0.24
-0.28
-1.29
-1.98
-2.36
-0.29
-0.59
- -
Dividend per Share
0.2
1.25
- -
0.25
0.25
0.11
0.05
0.06
0.06
0.07
0.11
0.11
0.1
0.09
Book Value per Share
1.28
1.12
3.71
3.89
3.89
3.92
4.03
4.12
6.57
5.83
3.24
2.26
1.74
4.87
Tangible Book Value per Share
1.08
0.95
3.41
3.55
3.46
2.51
2.3
2.63
5.29
4.69
1.01
0.27
0.19
3.26
Basic Weighted Avg Shares
112
56
112
141
140
137
140
140
149
159
159
159
159
161
Sales/Revenue/Turnover
178
254
309
313
296
402
415
368
370
386
423
441
416
429
Operating Margin (%)
36.21
37.06
35.43
20.48
9.62
3.65
3.38
3.51
-17.02
-57.17
-46.02
-10.02
-20.64
-19.7
Depreciation Expense
6
7
9
12
15
23
35
37
52
59
72
95
93
- -
Net Income, GAAP
57
84
103
66
34
16
11
15
-35
-127
-349
-156
-218
-210
Effective Tax Rate (%)
14.9
14.97
14.75
10.84
4.53
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
32.14
32.92
33.5
21.23
11.33
4.1
2.59
4.02
-9.42
-33.03
-82.46
-35.41
-52.32
-48.88
Working Capital
65
59
375
328
305
-30
-37
-37
248
-14
-148
-167
39
589
LT Debt
- -
- -
- -
- -
- -
- -
35
82
47
84
168
142
244
180
Total Equity
143
157
519
552
552
562
574
582
1,050
956
569
397
346
942
Return on Invested Capital (%)
42.42
51.49
28.29
11.53
6.38
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
45.47
55.82
30.62
10.67
4.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
45.5
55.85
30.62
12.4
6.08
2.98
1.92
2.6
-4.31
-12.92
-48.25
-35.66
-68.32
-37.76

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
246
295
305
LT Borrowings
241
181
179
LT Finance Leases
- -
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
159
159
168
Market Capitalization
15,798
17,143
14,060

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
526
464
1,139
Cash, Cash Equivalents & STI
209
164
826
Accounts Receivable, Net
81
73
78
Inventories
130
129
131
Total Current Liabilities
518
540
550
Payables & Accruals
- -
- -
- -
ST Debt
246
295
305
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-0.04%
-2.41%
-12.72%
Free Cash Flow
-90.86%
98.92%
104.41%
Net Income, GAAP
-4.53%
17.54%
39.37%
Sales/Revenue/Turnover
3.67%
2.6%
-5.68%
Total Cash Common Dividend
- -
14.6%
-11.83%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
120
98
108
115
441
2025
98
111
- -
101
416
2026
98
122
109
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.09
-0.13
-0.22
-0.54
-0.98
2025
-0.18
-0.24
- -
-0.67
-1.37
2026
-0.16
-0.27
-0.21
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.03
0.03
0.03
0.03
0.11
2025
0.02
0.02
- -
0.02
0.1
2026
0.02
0.02
0.02
- -
- -

Company Description

CEO
Guo Ping Li
Full Time Employees
715
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Building 16, Phase II Fuzhou FU China 350003
IPO Date
Apr 13, 2015
Business
Fujian Cosunter Pharmaceutical Co., Ltd. (300436.SZ) engages in the research, development, manufacture, and sale of pharmaceutical preparations and active pharmaceutical ingredients (APIs), with a focus on cardiovascular, cerebrovascular, and anti-tumor drugs. The company offers core products including cosunternib capsules for tumor treatment; injections such as cosunternib and irinotecan hydrochloride; and oral preparations like oseltamivir phosphate capsules and sustained-release tablets for antiviral applications; alongside APIs including high-end chemical drugs and contrast agents. It operates primarily in the pharmaceutical industry, targeting domestic hospitals, pharmacies, and distributors in China, with headquarters in Fuzhou, Fujian province, where it was founded in 2002. In recent developments, the company expanded its production capabilities through the completion of a new API project in 2024, enhancing capacity for key intermediates and boosting overall manufacturing efficiency. Additionally, Fujian Cosunter formed strategic partnerships with leading research institutions for new drug development pipelines, including Phase III clinical trials for innovative cardiovascular therapies announced in late 2024. No major acquisitions, funding rounds, or name changes were reported in the last 1-2 years, though the firm continues to invest in R&D for biologics and expanded its geographic footprint within China via new distribution agreements.